---
document_datetime: 2023-09-21 17:08:42
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/refacto-af-epar-procedural-steps-taken-authorisation_en.pdf
document_name: refacto-af-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4039562
conversion_datetime: 2025-12-20 12:42:15.722993
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  company  Genetics  Institute  of  Europe  B.V.,  Germany,  submitted  on  6  February  1998  an application  for  Marketing  Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal Products (EMEA) for ReFacto, through the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No. (EC) 2309/93 of 22 July 1993.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur:

Dr. G. Jensen

Co-Rapporteur:

Dr. van der Giesen

## Licensing status:

A new drug application was filed in the following countries: USA, Switzerland and Canada.

The product was not licensed in any country at the time of submission of the application

## 2. Steps taken for the assessment of the product

- The procedure started on 27 February 1998.
- The Rapporteur's first assessment report was circulated to all CPMP Members on 13 May 1998. The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on  4 May 1998.
- During the meeting on 23 June 1998, the CPMP agreed on the consolidated list of questions to be  sent  to  the  company.  The  final  consolidated  list  of  questions  was  sent  to  the  company  on 25 June 1998.
- The company submitted the responses to the consolidated list of questions on 28 August 1998.
- The Rapporteur and the Co-Rapporteur circulated the joint assessment report on the company's responses to the list of questions to all CPMP Members on 19 October 1998.
- During  the  meeting  of  17-19  November  1998,  the  CPMP  adopted  a  list  of  outstanding pharmaceutical issues to be addressed by the company prior to the opinion and additional issues to be addressed on a post-opinion basis. The list of outstanding issues adopted by the CPMP was sent to the company on 17 November 1998.
- The applicant at the December BWP meeting gave an oral presentation of the results of new virus validation studies performed. The BWP on 9 December 1998 adopted a recommendation to the CPMP in their meeting in December.
- During  the  meeting  of  15-17  December  1998,  the  CPMP  discussed  the  recommendations presented  by  the  Rapporteur  and  considered  satisfactory  the  responses  submitted  by  the company.
- The Company signed a letter of undertaking regarding the follow-up measures on 15 December 1998
- During  the  meeting  of  15-17  December  1998,  the  CPMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee  issued  a  positive  opinion  for granting a Marketing Authorisation to ReFacto on 17 December 1998.